Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Gynecologic 1

Conditions

Uterine Cervical Neoplasms 9Ovarian Neoplasms 9Colorectal Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Peritoneal Neoplasms 2Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Cetuximab × Gynecologic × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡